Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
Glaukos Corporation (NYSE: GKOS) is set to release its fourth quarter and full year 2023 financial results on February 21, 2024. The company, focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases, will host a conference call and webcast to discuss the results. The live webcast link will be available on the company's website, and a replay will be archived afterward.
01/31/2024 - 07:00 AM
Conference Call and Webcast Scheduled for 1:30 p.m. PT
ALISO VIEJO, Calif. --(BUSINESS WIRE)--
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 21, 2024.
A link to the live webcast will be available on the company’s website at http://investors.glaukos.com . To participate in the conference call, please dial 888-210-2212 (U.S. ) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.
About Glaukos
Glaukos (www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131248268/en/
Chris Lewis
Vice President, Investor Relations and Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
Glaukos Corporation will release its fourth quarter and full year 2023 financial results after the market close on February 21, 2024.
Glaukos Corporation focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. The live webcast link will be available on the company's website at http://investors.glaukos.com.
A replay of the conference call will be archived on the company's website following completion of the call.
GKOS Rankings
#908 Ranked by Stock Gains
GKOS Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
San Clemente
About GKOS
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde